Journal of Clinical Oncology
Articles in this Issue
Examining the impact of TGF-ß activity on fibroblast infiltration and immune exclusion in MIBC.
851 Background: In urothelial cancer, transforming growth factor β (TGF-β) signaling in fibroblasts has been correlated wi...
Saruparib + androgen receptor pathway inhibitor (ARPI) + androgen deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): The phase 1/2 PETRANHA trial.
177 Background: Poly(ADP-ribose) polymerase inhibitors (PARPi) + ARPI + ADT have improved clinical outcomes versus ARPI +...
Heterogeneity and synergistic inhibition of the poly(ADP-ribose) polymerase and androgen receptor signaling pathway in patients with metastatic castration-resistant prostate cancer.
236 Background: Our previous study demonstrated that olaparib combined with abiraterone improves survival outcomes in meta...
Contemporary survival and treatment outcomes in malignant spermatic-cord tumors: A two-decade population-based analysis.
593 Background: Malignant spermatic-cord tumors (SCTs) are exceedingly rare, and population-level survival data in the mod...
Association of SETD2 mutation with prognostic features and susceptibility to acute kidney injury in renal cell carcinoma.
554 Background: Renal cell carcinoma (RCC) ranks 8 most lethal cancers and is responsible for about 140,000 deaths worldwi...
The diversity and clinical relevance of germline DNA damage repair gene variants in 3005 patients with metastatic prostate cancer.
227 Background: Inherited genetic variants in genes linked to DNA damage repair (DDR) can increase the risk of developing...
Rucaparib vs docetaxel (DTX) or second-generation androgen receptor pathway inhibitor (ARPI) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with <i>BRCA</i> mutations based on Eastern Cooperative Oncology Group performance status (ECOG PS) in TRITON3.
46 Background: Primary results from the randomized, multicenter, open-label, phase 3 TRITON3 (NCT02975934) study demonstra...
Conventional-dose chemotherapy as first salvage in germ cell tumors: Outcomes from an Ibero-American multi-institutional cohort.
597 Background: In relapsed or refractory germ cell tumors, two salvage strategies are commonly used: conventional-dose ch...
Unveiling sex-based disparities in advanced renal cell carcinoma: Insights from the real-world Meet-URO33 (REGAL) study.
526 Background: Sex-related biological differences may affect cancer immunity and outcomes with immune checkpoint inhibito...
Evaluation of PSA decline patterns in the Chinese subgroup of LIBERTAS, a phase 3 study of apalutamide plus continuous versus intermittent androgen deprivation therapy in metastatic castration-sensitive prostate cancer.
154 Background: LIBERTAS is a global phase 3 study evaluating apalutamide (APA) plus intermittent versus continuous androg...
Effect of programmed cell death protein ligand 1 nuclear translocation mediated by Enolase on urothelial carcinoma immune evasion.
788 Background: The efficacy of programmed death-ligand 1 (PD-L1)-based immunotherapy is limited in urothelial carcinoma (...
Trends in prostate cancer mortality after the 2012 USPSTF PSA guideline: Comparisons with kidney cancer and racial disparities.
325 Background: In 2012, the USPSTF issued a Grade D recommendation against PSA-based screening for prostate cancer. While...
Postoperative surveillance in non clear cell renal cancer: Is current practice best practice?
435 Background: Current American Urologic Association (AUA) and National Comprehensive Cancer Network (NCCN) guidelines do...
A randomised, multicentre, phase II trial of active surveillance with or without six months of apalutamide for prostate cancer.
363 Background: Active surveillance (AS) is standard of care for low-risk and selected intermediate risk prostate cancer (...
Clinical, radiographic, and genomic predictors of response to neoadjuvant chemotherapy for high-risk localized upper tract urothelial carcinoma.
861 Background: Recent data support a pathologic response in 60-65%, including 10-20% with a pathologic complete response...
A multi-institution analysis of outcomes with first-line ipilimumab and nivolumab for 514 patients with metastatic clear cell renal cell carcinoma by number of doses.
441 Background: Ipilimumab (IPI) and nivolumab (NIVO) are a standard first line systemic therapy option for patients with...
Association between non-luminal molecular subtypes and complete response rates after neoadjuvant chemo-immune therapy for muscle-invasive bladder cancer: Biomarker analyses of NURE-combo and BLASST-01 phase 2 clinical trials.
845 Background: The BLASST-01 (NCT03294304) and NURE-combo (NCT04876313) clinical trials evaluated the use of neoadjuvant...
ProTACT: A first-in-human, phase 1 dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity of [ <sup>225</sup> Ac]Ac-FL-020, an anti-PSMA radioconjugate in patients with mCRPC.
TPS282 Background: Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy is an emerging treatment modalit...
Antibody-drug conjugates in genitourinary malignancies: The clinical trial landscape and emerging efficacy benchmarks.
877 Background: Antibody-drug conjugates (ADCs) are increasingly likely to transform the treatment of genitourinary (GU) m...
Clinical and genomic characteristics of advanced urothelial carcinoma (UC) patients (pts) who fail therapy with enfortumab vedodin (EV) plus pembrolizumab (P).
685 Background: EV plus P has become the standard-of-care first-line therapy for most pts with advanced UC in the United S...
Impact of HER2 expression and <i>ERBB2</i> alterations on clinical outcomes in patients treated with enfortumab vedotin and pembrolizumab (EVP): UNITE study analysis.
794 Background: HER2 protein, encoded by ERBB2 gene, is the target of emerging the...
Dynamic investigator initiated enterprise (DIVINE) in prostate cancer: Randomized phase II trial of stereotactic body radiotherapy with or without short-course androgen deprivation and AR pathway inhibition in oligometastatic castration-sensitive prostate cancer.
TPS283 Background: Emerging evidence suggests that metastasis-directed therapy (MDT) with stereotactic body radiotherapy (...
Quantifying the value of tumor response and survival: Perceived monetary loss in anticancer therapy.
878 Background: The clinical benefit of anticancer therapy is usually evaluated using endpoints such as tumor response or...
Circulating tumor DNA analysis from the prospective pT0 study of systematic endoscopic evaluation in patients undergoing radical cystectomy for bladder cancer.
837 Background: We published a prospective trial of Systematic Endoscopic Evaluation (SEE) prior to radical cystectomy (RC...
Impact of bleomycin dose omissions on clinical outcomes in non-seminomatous germ cell tumors: A systematic review and meta-analysis.
612 Background: Non-seminomatous germ cell tumors (NSGCT) represent the most curable solid malignancies in young men with...